Method of preparation of aqueous solutions of vincristin and vinblastin

专利摘要:
According to the invention there is provided complexes formed between a bis-indole compound and a bi- or multivalent metal ion, as well as a process for the preparation of a pharmaceutically acceptable metal complex of a bis-indole compound and, optionally, aqueous pharmaceutical compositions containing said metal complexes which are of substantially increased stability, in which process a solution of a bis-indole compound or a pharmaceutically acceptable salt thereof in an aqueous medium is reacted with a non-toxic water soluble salt of a bi- or multivalent metal capable of complexation, at a pH of 3.0 to 6.0, optionally in the presence of or followed by the addition of a conventional pharmaceutical carrier and/or further additive, or, if desired, the obtained complex is isolated. Specifically, the complexes of vinblastine and vincristine with Zn(II), Ca(II) or Mg(II) are disclosed.
公开号:SU1706372A3
申请号:SU853963551
申请日:1985-10-15
公开日:1992-01-15
发明作者:Такачи Надь Геза；Сепеши Габор；Газдаг Мария；Пап Жофия；Бургер Кальман
申请人:Рихтер Гедеон Ведьесети Дьяр Рт (Инопредприятие)；
IPC主号:

专利说明:

The invention relates to the chemical and fermus industry, in particular, to methods for preparing aqueous solutions of vincristine and vinblastine.
The purpose of the invention is to increase stability.
Example 1. The solution contains, g:
Vincristine sulfate, 0, 1 Propyl-vapor-benzoate, 0.02; Acetic acid, 0.025; Calcium gluconate; H2O, 0.05;
Methyl paraoxybenzoate 0.13 Ethanol (96%) 5 Mannitol 10 Leaf water, suitable for quality
Injections Up to 100 ml In freshly prepared and nitrogen-saturated distilled water in an amount not reaching a whole number of times the quality is suitable for injection, mannitol, calcium gluconate and sodium acetate are dissolved and the prescribed amount of acetic acid is added. The nip ether (propyl paraoxybenzoate and methyl paraoxy benzoate) is dissolved in 96% ethanol, then the resulting solution

cm
31
with the basic solution obtained by the above method. Vincristine sulfate is then added, dissolved separately in a small amount of distilled water. The volume of the solution is supplemented with distilled water of suitable quality for injection to the final volume, then the solution is homogenized, subjected to sterile filtration and filled with sterile glasses in an inert gas atmosphere.
Example 2. The solution contains: g: Vincristine sulfate 0.1 Propyl-paraoxybenzoate 0.005 h Magnesium gluconate 0, Acetic acid (983-na) 0.025 Sodium acetate xZN200, 0256 Methyl paraoxybenzoate 0.05 Ethanol (96% ) 5 Mannitol 5 Distilled water, suitable for injection. Up to 100 ml. The solution is prepared according to Example 1.
Example 3. The solution contains: g: Vincristine sulfate 0.1 Acetic acid (931-na) 0.025 Zinc gluconate 0, sodium acetate ЗН20 0.06 Benzyl alcohol 0.9 Ethanol () 5 Mannitol 5 Distilled water, suitable for quality
Injections Up to 100 ml In freshly prepared and nitrogen-saturated distilled water in an amount not reaching a whole number of times, in terms of quality suitable for injections, mannitol and glucose of zinc are dissolved, then acetic acid and a mixture of ethanol and ben-ethyl alcohol are added to the solution. Vincristine sulfate, dissolved separately in a small amount of dis2, is added.
tilled water. The solution is supplemented with distilled water of suitable quality for injection to the final volume, then the solution is homogenized and, after sterile filtration, is filled with sterile glasses in an inert gas atmosphere.
Example C. the Solution contains, g:
Vincristinao sulphate 1 Propyl-paraoxy-benzoate 0.005 Calcium acetate H 0,00 0.0222 Acetic acid (98%) 0.025 Sodium acetate ZH20 0.0256 Methyl-paracecobenzoate 0.05 Ethanol (96%) 5 Mannitol 5 Distilled water suitable for quality
injections up to 100 ml. The solution is prepared according to example 1.
Example 5. Solution coqepzhit, g:
Vincristine sulfate 0.1 Acetic acid (98%) 0.025 Sodium acetate xZN200, 026 Calcium gluconate 0.056 Benzyl alcohol 0.9 Sorbitol 5 Polyethylene glycol 00 10 Distilled water, suitable for quality
Qo injections of 100 ml In freshly prepared and nitrogen-enriched distilled water in an amount not reaching an integer number, suitable for injection, sorbitol and calcium gluconate are successively dissolved. Then acetic acid and a mixture of benzyl alcohol with polyethylene glycol are added. After that, vincristine sulfate is added, dissolved separately in a small amount of distilled water, and the solution is added.
five
distilled water, suitable for injection quality, to final volume. After homogenization and filtration, the solution is poured into sterile glasses in an inert gas atmosphere.
Example 3t Solution contains, g:
Vinblastine sulfate 0.1
Propyl-paraoxybenzoate, 005
Calcium Acetate
H200.023 Acetic Acid (98%) 0.049 Sodium Acetate
3ngo0
Methyl paraoxybenzoate0.05
Ethanol (9bЈ-ny) 5
Mannit5
Distilled
water by quality
suitable for
injections about 100 m
The solution is prepared according to example 1.
Example 7. The solution contains, g:
Vincristine sulfate 0.1
Propyl-paraoxybenzoate0,02
Acetic acid (96%) 0.025
Zinc Sulphate
Sodium acetate
ZN200.06 Methyl paraoxybenzoate 0.13 Methanol (97%) 5 Mannitol 10 Distilled water, suitable for quality
injections up to 100 m. The solution is prepared according to example 1.
Sustainability research.
The stability of the solutions containing vincristine sulfate obtained by the method according to the invention was monitored by means of chromatography with viewport-based fluids (HPhC).
HPhC method for determining vincristine content: pillar - nucle063726
zil 6 C3, 250, 6 mm (Khrompak), the solvent is a mixture of methanol, j and diethylamine, the wavelength is 297 nm,
with a flow rate of 2 ml / min.
The content of the active principle was determined in comparison with a pure aqueous solution of vincristine sulfate of the same origin and concentration with the test solution (injection) of vincristine sulfate.
Accelerated sustainability research.
The table summarizes the results of the core research on sustainability. A comparison was made of the stability of the preparation according to Example 1 prepared according to the invention (solution 1) and the stability obtained
20 according to example 1 of the known preparation (solution 3) and the single-ampule preparation for injection Oncovin (solution 2). The solutions under the same conditions were subjected to heat treatment in
25 for days at 75 ° C.
From the data in the table it can be seen that the complex compound Ca and vincristine obtained in accordance with the invention in the form of stabilized
The 30 preparations for injection has, with accelerated stability studies, a significantly better stability compared to known solutions. A long-term sustainability study. From the prepared vincristine sulfate solution prepared in Example 1 with a concentration of 1 mg / ml of the active principle, was poured into 3 ampoules
40 5 ml o Permanent storage of the solutions at 5 ° C showed that during storage for 12 months there was practically no decomposition.

权利要求:
Claims (1)
[1]
45 claims
The method of obtaining aqueous solutions of vincristine or vinblastine by mixing one of them with a solvent, acetate buffer solution, characterized in that, in order to increase stability, the metal complex compound of zinc or calcium or magnesium is added at a ratio of 1 mole of vincristine or vinblastin 1 g-eq complexing metal.
Reception. Okraskch marked according to Ph. Hp, vi,

类似技术:

---

公开号 | 公开日 | 专利标题

---

Finnegan et al.1986|Neutral water-soluble aluminum complex of neurological interest

---

Shionoya et al.1992|Diprotonated sapphyrin: a fluoride selective halide anion receptor

---

Fischer et al.1976|The structure of the heteropolytungstate | 17NA| NaW21Sb9O86|. cntdot. 14H2O. An inorganic cryptate

---

CA1273578A|1990-09-04|Basic formulations of quinolonecarboxylic acids

---

SU1706372A3|1992-01-15|Method of preparation of aqueous solutions of vincristin and vinblastin

---

EP0411935A2|1991-02-06|Copper radio sensitizers

---

Gillen et al.1975|The Use of the n-Propylammonium and n-Butylammonium Saltsof d-10-Camphorsulfonic Acid for the Calibration of Spectropolarimeters: Circular Dichrometer Calibration

---

Hartree1953|On the configuration of the so-called dihydroxymaleic acid

---

Dwyer et al.1956|Resolution of Tris-oxalato Metal Complexes.

---

FR2650280A1|1991-02-01| -1,2-EPOXYPROPYL-PHOSPHONATE OF MONO- | HAVING IMPROVED STABILITY CHARACTERISTICS, PROCESS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME

---

KR0164601B1|1999-01-15|Injectable solution containing a bis-indole alkaloid salt and process for preparing the same

---

Kolthoff et al.1976|Intramolecular hydrogen bonding involving hydroxyl groups in mono-and dianions of diprotic acids in acetonitrile and dimethyl sulfoxide

---

Cartledge et al.1936|An Oxalato Complex of Quadrivalent Manganese

---

HU181940B|1983-11-28|Process for producing solutions of vincane derivatives for parentheral application

---

CA1080621A|1980-07-01|Aqueous solution and preparation thereof

---

CN105125481A|2015-12-09|Methylergometrine maleate injection and preparation method thereof

---

RU2277085C1|2006-05-27|Method of determining glycine in an aqueous solution

---

Jemal et al.1978|Demonstration of penicillamine as a product in benzylpenicillenic acid degradation in neutral media using differential pulse polarography

---

Yeh1959|STABILITY OF MORPHINE IN AQUEOUS SOLUTION.

---

Rao et al.2000|Complexation of thorium | with desmethyldesferrithiocin

---

Schilt et al.1973|Reactions of cyanopentaaquachromium | ion

---

RU2049468C1|1995-12-10|Method of preparing agent showing antitumor activity

---

RU2255082C2|2005-06-27|Heterometallic neodymium | and iron | malate and a method for preparation thereof

---

SU1090404A1|1984-05-07|Method of preparing sibasone solution for injections

---

Corlett et al.1970|Polystyrene sulfonates as stable polarographic maxima suppressors in the determination of periodate and cobalt |

同族专利:

---

公开号 | 公开日

---

IT8522482D0|1985-10-15|

---

HU195513B|1988-05-30|

---

DK472085D0|1985-10-15|

---

IE58467B1|1993-09-22|

---

SE8504786L|1986-04-17|

---

IL76719A|1989-10-31|

---

DD239207A5|1986-09-17|

---

CN85107053A|1986-06-10|

---

NL192779B|1997-10-01|

---

FI84134C|1991-10-25|

---

LT2203B|1993-10-15|

---

SE8504786D0|1985-10-15|

---

DE3536745C2|1992-01-23|

---

DE3536745A1|1986-04-17|

---

GB2165540A|1986-04-16|

---

GR852510B|1986-02-18|

---

GB2165540B|1988-04-27|

---

DK169972B1|1995-04-18|

---

ATA297985A|1989-08-15|

---

CA1272192A|1990-07-31|

---

JPS61106584A|1986-05-24|

---

FR2571724B1|1988-08-26|

---

LU86115A1|1986-03-24|

---

LV5175A3|1993-10-10|

---

FI853123A0|1985-08-15|

---

US4684638A|1987-08-04|

---

FR2571724A1|1986-04-18|

---

FI84134B|1991-07-15|

---

AU4871485A|1986-04-24|

---

NL8502821A|1986-05-16|

---

CS251798B2|1987-08-13|

---

IE852531L|1986-04-16|

---

IT1186776B|1987-12-16|

---

DK472085A|1986-04-17|

---

CN1007958B|1990-05-16|

---

NL192779C|1998-02-03|

---

ZA857905B|1986-06-25|

---

ES8701185A1|1986-11-16|

---

SE466017B|1991-12-02|

---

AU580342B2|1989-01-12|

---

ES547862A0|1986-11-16|

---

JPH0339489B2|1991-06-14|

---

CH667459A5|1988-10-14|

---

BE903447A|1986-04-15|

---

IL76719D0|1986-02-28|

---

AT389996B|1990-02-26|

---

IN162910B|1988-07-23|

---

FI853123L|1986-04-17|

---

GB8525360D0|1985-11-20|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

DE595570C|1932-10-07|1934-04-16|I G Farbenindustrie Akt Ges|Process for the preparation of aqueous solutions of heavy metal compounds of the aromatic halyl sulfamides|

---

US3426024A|1967-11-17|1969-02-04|Vanderbilt Co R T|Amine complexes of zinc salts of chlorinated thiobisphenols|

---

DE2502932C2|1975-01-24|1985-04-18|Bayer Ag, 5090 Leverkusen|Metal complexes of N-trityl-azoles, processes for their preparation and their use as fungicides|

---

FR2349335B1|1976-04-28|1979-10-05|Inst Int Pathologie Cellulaire|

---

EP0004770B1|1978-04-11|1984-06-13|Efamol Limited|Pharmaceutical and dietary composition comprising gamma-linolenic acids|

---

AT11014T|1981-07-14|1985-01-15|Efamol Limited|PHARMACEUTICAL AND DIETETARY COMPOSITION FOR INCREASING SERIES L-PG PRODUCTION.|

---

IT1170152B|1982-07-19|1987-06-03|Lilly Co Eli|IMPROVEMENTS TO OR CONCERNING VINCA-ALCALOID FORMULATIONS|CA1341262C|1987-08-06|2001-06-26|Camille A. Boulet|A new process of the synthesis of 3',4'-anhydrovinblastine, vinblastine and vincristine|

---

US5170515A|1987-09-16|1992-12-15|Toto Ltd.|Water closet|

---

FR2623089B1|1987-11-13|1990-04-27|Pf Medicament|PHARMACEUTICAL COMPOSITION FOR PARENTERAL ADMINISTRATION OF NAVELBINE|

---

HU204995B|1989-11-07|1992-03-30|Richter Gedeon Vegyeszet|Process for producing pharmaceutical composition comprising alkaloid with bis-indole skeleton, with antitumour activity and suitable fr parenteral purposes|

---

FR2863891B1|2003-12-23|2006-03-24|Pf Medicament|PHARMACEUTICAL COMPOSITION OF VINFLUNIN FOR PARENTAL ADMINISTRATION, PROCESS FOR PREPARATION AND USE|

---

US20110015221A1|2003-12-23|2011-01-20|Pierre Fabre Medicament|Pharmaceutical composition of vinflunine which is intended for parenteral administration preparation method thereof and use of same|

---

WO2007047951A2|2005-10-20|2007-04-26|University Of South Florida|Molecular delivery to cells using aspirin-related compounds|

法律状态:

优先权:

---

申请号 | 申请日 | 专利标题

---

HU843861A|HU195513B|1984-10-16|1984-10-16|Process for producing stable solutions of alkaloides with bis-indole skeleton|LV930046A| LV5175A3|1984-10-16|1993-01-18|Vincristine and Vinblastine Water Skimming Saturation|

---

LTRP858A| LT2203B|1984-10-16|1993-08-13|THE BUDGET FOR RECEIVING THE WATER SOLUTION FOR VINCASTLAST OR VINBLAST|